If you're pursuing a treatment compound or device for respiratory and lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancers, cystic fibrosis (CF) or idiopathic pulmonary fibrosis we can give you access to preclinical pharmacological PD models, an extensive inhalation team and facility and medical device development as well as clinical trials and post-market reimbursement strategies.
Respiratory and lung disease development, including inhalation administration routes, from preclinical to post-market
Inhalation: Route of administration and delivery
Many respiratory and lung treatment compounds require specialized inhalation testing to appropriately deliver the drug. With a purpose-built facility just for inhalation studies and well-known scientists in the field of inhalation delivery, we can help you get your inhaled treatment to market quickly and effectively.
- More than 150 inhalation studies performed annually
- Aerosolization engineering capabilities
- Regulatory experience with inhaled medicines, respiratory diseases and medical devices.
NEW INHALATION BUILDOUT
Breathing new life into inhaled medicines
The inhaled medicine market is booming with over 100 pharmaceutical compounds in development for the treatment of respiratory ailments. We are responding to this rapid growth with an estimated $10 million expansion. Read all about our investments in inhalation.